Carregant...
What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment
Polycystic ovary syndrome, the most common gynecological endocrinopathy, is burdened with a state of hyperinsulinemia and insulin resistance in 50–80% of affected women. Wherever the origin of these metabolic abnormalities lies, their pathogenetic role in determining, perpetuating, and worsening the...
Guardat en:
| Publicat a: | Ther Adv Reprod Health |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7236839/ https://ncbi.nlm.nih.gov/pubmed/32435760 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2633494120908709 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|